HER2-positive breast cancer - Cleveland Clinic

Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}}
Now: 1769985067433
Cache Key: cqdTagPageBySlug:her2-positive-breast-cancer
fetchCache[cqdTagPageBySlug:her2-positive-breast-cancer].expirationTime: falsey
fetchCache[cqdTagPageBySlug:her2-positive-breast-cancer]. seconds remaining: falsey
All fetchCache expiration times:
-- Key: cqdNotFoundPage, seconds remaining: -170392
-- Key: cqdTagPageBySlug:geriatric-innovations, seconds remaining: -23259341
-- Key: cqdPostsByTag:cqd-migrated-tag-22207,1,10, seconds remaining: -23259239
-- Key: cqdTagPageBySlug:american-society-of-reproductive-medicine-asrm, seconds remaining: -1753024
-- Key: cqdPostsByTag:cqd-migrated-tag-17615,1,10, seconds remaining: -1752958
-- Key: cqdTagPageBySlug:functional-status, seconds remaining: -170392
-- Key: cqdPostsByTag:cqd-migrated-tag-20243,1,10, seconds remaining: -170324
conditions:
-- false,
-- NA,
-- NA,
-- NA
-- false
Cache miss for key cqdTagPageBySlug:her2-positive-breast-cancer - retrieving from Sanity
CCCache.dataFetchCount: 49
Cache cleanup seconds remaining: 30000

Tag: HER2-positive breast cancer

Real-World Data Reveals Gap Between Guidelines and Practice in HER2+ Breast Cancer Care

Trastuzumab Deruxtecan Improves Invasive Disease-Free Survival of Early-Stage HER+ Breast Cancer by 53%

When Is De-escalating Systemic Therapy Appropriate in Low-Risk Breast Cancer?

Global Trial Seeks New Gold Standard Treatment for HER2+ Early Breast Cancer in Post-Neoadjuvant Setting

Adjuvant T-DM1 Superior to Trastuzumab in Patients with HER2+ Early Breast Cancer